Search

Displaying results 5401 - 5410 of 10000 in total
  1. Drug

    Alkaline Phosphatase

    go.drugbank.com/drugs/DB05768
    Investigational

    AP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from Gram-negative bacteria and extracellular ATP in UC patients.

  2. Drug

    Parnaparin

    go.drugbank.com/drugs/DB09260
    Approved

    Parnaparin is an heparin of low molecular weight with antithrombotic effects.

  3. Drug

    Linifanib

    go.drugbank.com/drugs/DB06080
    Investigational

    Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels … Linifanib is intended for the treatment of hematologic malignancies and the solid tumors.

    Categories: Receptor Protein-Tyrosine Kinases, antagonists & inhibitors
  4. Drug

    4-Hydroxytestosterone

    go.drugbank.com/drugs/DB01485
    IllicitInvestigational

    It is specifically the 17-hydroxylated analog to formestane. … 4-Hydroxytestosterone is testosterone substituted with a hydroxy group on the fourth carbon atom.

  5. Drug

    NKG2D-ACE2 CAR-NK Cell

    go.drugbank.com/drugs/DB15727
    Investigational

    The ACE2 is a receptor for SARS-Cov-2, binding to the S-protein of the viral envelope and competitively inhibiting SARS-Cov-2 infection of type II alveolar epithelial cells. … Chimeric antigen receptors (CARs) are artificial receptors consisting of an antibody-derived antigen binding domain and transmembrane and signaling domains from T-cell receptor signalling moieties.

  6. Drug

    DYNE-251

    go.drugbank.com/drugs/DB18130
    Investigational

    DYNE-251 is a phosphorodiamidate morpholino oligomer (PMO) conjugated to a fragment antibody (Fab) that binds to the transferrin receptor 1 (TfR1). … It is being investigated for the treatment of Duchenne muscular dystrophy (DMD) in patients who are amenable to exon 51 skipping.

  7. Drug

    N-Methylmesoporphyrin

    go.drugbank.com/drugs/DB01911
    Experimental

    This compound belongs to the porphyrins. … This medication is known to target ferrochelatase.

  8. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … [L11100] Clinical trials are expected to begin in 2020.[L11103,L11100]

  9. Drug

    AGS-005

    go.drugbank.com/drugs/DB05741
    Experimental

    AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's

  10. Drug

    Motexafin lutetium

    go.drugbank.com/drugs/DB05296
    Investigational

    It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.